Selexipag Tablet, Film Coated
Product Images NDC 70771-1795

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Selexipag (NDC 70771-1795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 01)

Chemical structure of Selexipag displayed as a 2D molecular diagram showing the arrangement of atoms and bonds characteristic of this active pharmaceutical ingredient.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 02)

A chart depicting the fold-change in pharmacokinetic parameters AUC and Cmax for Selexipag and its active metabolite when co-administered with various interacting drugs including gemfibrozil, clopidogrel, lopinavir/ritonavir, rifampin, warfarin, and a PDE-5 inhibitor. The x-axis shows fold-change relative to Selexipag alone on a logarithmic scale from 1/10 to 10, with point estimates and 90% confidence intervals displayed as error bars.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 03)

A figure presenting the fold-change in AUC and Cmax pharmacokinetic parameters for R-warfarin, S-warfarin, midazolam, and 1OH-midazolam when administered with Selexipag compared to the drugs alone. The chart shows point estimates and 90% confidence intervals relative to the control drugs without Selexipag.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 04)

A Kaplan-Meier survival curve chart showing the percentage of patients event-free over 36 months from randomization, comparing Selexipag (solid line) and placebo (dotted line). The graph includes patient numbers at risk at various time points and statistical data (hazard ratio, confidence interval, p-value) indicating a difference between Selexipag and placebo groups.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 05)

A line graph comparing estimated cumulative probabilities over months from randomization between Selexipag and placebo patients. The x-axis shows time in months (0 to 36), and the y-axis shows estimated cumulative probability in percent (0% to 40%). Two lines represent Selexipag and placebo groups, with data points at risk below the x-axis for both groups over time.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 06)

A line graph showing estimated cumulative probability percentages over 36 months from randomization for Selexipag versus placebo. Two stepwise curves compare outcomes for Selexipag patients and placebo patients, with patient counts at risk provided below the x-axis for both groups over time.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 07)

A cumulative probability graph displaying the estimated event occurrence over 36 months from randomization for Selexipag patients compared to placebo patients. The plot shows two lines, one solid for Selexipag and one dotted for placebo, with patient numbers at risk listed below the x-axis at various time points. The y-axis represents estimated cumulative probability percentage, ranging from 0 to 40%. The x-axis represents months from randomization, ranging from 0 to 36 months.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 08)

A forest plot chart showing hazard ratios and 99% confidence intervals for Selexipag versus placebo across various subgroups, including overall treatment effect, PAH therapy status, WHO functional class, sex, race, age at screening, PAH etiology, and geographical region. The plot indicates effect sizes favoring Selexipag with numerical HR and CI values listed for each subgroup.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 09)

Label for Selexipag Tablets 200 mcg film-coated oral tablets by Zydus Lifesciences Limited. The label shows the product name, dosage strength (200 mcg), package quantity (60 tablets), and storage instructions. The label also includes a barcode and notes that the package is child-resistant and dispensed by prescription only.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 10)

Label for Selexipag Tablets 400 mcg film-coated tablets. The label shows the product name, strength, form, and quantity (60 tablets). It includes storage instructions, a warning to keep out of reach of children, and states the product is prescription only. The labeler is Zydus Lifesciences Limited, Ahmedabad, India.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 11)

The packaging label for Selexipag Tablets 600 mcg film-coated tablets by Zydus Lifesciences Limited. The label includes NDC 70771-1795-6, states the package contains 60 tablets, and provides storage instructions. Safety warnings indicate the package is child-resistant and to keep out of children's reach, with dispensing noted as Rx only.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 12)

Selexipag Tablets 800 mcg film-coated oral tablets label shows product name, strength, quantity of 60 tablets, and manufacturer Zydus Lifesciences Limited. The label includes storage instructions, dosage form, and child-resistant packaging notice. The NDC is 70771-1796-6, with a barcode and batch information placeholders.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 13)

Label for Selexipag Tablets 1,000 mcg, a film-coated oral tablet by Zydus Lifesciences Limited. The label indicates a package of 60 tablets, prescription only, with storage instructions and child-resistant packaging. Manufacturer details include Zydus Lifesciences Ltd., Ahmedabad, India.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 14)

Label for Selexipag Tablets 1,200 mcg, film-coated oral tablets. The label includes the NDC number 70771-1798-6, indicates a package of 60 tablets, and states Rx only. Manufactured by Zydus Lifesciences Limited. The label also includes dosage information and storage instructions.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 15)

Label for Selexipag Tablets 1400 mcg film-coated oral tablets by Zydus Lifesciences Limited. The label indicates a package containing 60 tablets, prescription only, with storage instructions and child-resistant packaging information. The product's NDC number 70771-1799-6 is visible, along with manufacturer details from Ahmedabad, India.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 16)

Selexipag Tablets 1600 mcg film-coated tablets label from Zydus Lifesciences Limited. The label includes dosage strength 1,600 mcg, package size of 60 tablets, and storage instructions. It also displays the NDC 70771-1800-6, barcode, and warnings about child resistance and keeping out of reach of children.*

FDA Label Image

Image (2eab2a03 A903 483f A6bc 606bc0d3d0ab 17)

Packaging label for Selexipag tablets featuring two strengths: 200 mcg and 800 mcg. The label identifies the product as film-coated oral tablets supplied in a titration pack with 140 tablets of 200 mcg and 60 tablets of 800 mcg. Manufactured by Zydus Lifesciences Ltd., Ahmedabad, India, with branding from Zydus Pharmaceuticals USA. Includes storage and dosage instructions on the side panel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.